Theravance Biopharma TBPH Business Segments — Stock-Based Comp
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's business segments — stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's business segments — stock-based comp?
- Theravance Biopharma (TBPH) reported business segments — stock-based comp of $3.48M in Q1 2026.
- How has Theravance Biopharma's business segments — stock-based comp changed year-over-year?
- Theravance Biopharma's business segments — stock-based comp decreased by 28.7% year-over-year, from $4.88M to $3.48M.
- What is the long-term trend for Theravance Biopharma's business segments — stock-based comp?
- Over 2 years (2023 to 2025), Theravance Biopharma's business segments — stock-based comp has grown at a -14.1% compound annual growth rate (CAGR), from $25.01M to $18.48M.
- What does business segments — stock-based comp mean?
- This represents the non-cash expense related to equity-based awards granted to employees and executives as part of their total compensation package. It is a critical metric for understanding the dilution impact and the alignment of management incentives with shareholder interests.